- Product Description Description
- Table of Contents TOC
- List of Table & Figure LOT
- Get Free Sample PDF Sample PDF
Market Size, 2025
$1.39 BnMarket Estimate, 2026
$1.55 BnMarket Forecast, 2034
$3.68 BnCAGR, 2026–2034
11.44%Executive Summary: Asia Pacific Viscosupplementation Market
- Market Scope: Comprehensive regional viscosupplementation market analysis covering product types, end-use settings, country-level frameworks, and therapeutic adoption metrics across the Asia Pacific.
- Market Valuation: Valued at USD 1.39 billion (2025), estimated at USD 1.55 billion (2026), and projected to reach USD 3.68 billion by 2034, registering a strong CAGR of 11.44% (2026–2034).
- Primary Growth Drivers: Rising prevalence of osteoarthritis among the aging population (with nearly half of older adults in APAC affected and high knee OA rates in countries like China), strong patient preference for non-surgical injection-based treatments, and continuous technical advancements in hyaluronic acid therapies. Key restraints include the high cost of treatment procedures, potential side effects, strict government policies, and a shortage of skilled professionals.
Key Market Segment Metrics (2026–2034)
| Category | Leading Segment (2025 Position) | Fastest-Growing Segment |
|---|---|---|
| By Product | Three Injection Regimen (traditionally led therapeutic application and clinical usage) | Single Injection (growing rapidly due to patient convenience and reduced clinical visits) |
| By End-Use | Hospitals (represented the largest treatment volume and infrastructure base) | Orthopedic Clinics and Ambulatory Surgical Centers (ASCs) |
| By Country / Region | China (accounted for the major chunk of the APAC regional market share driven by high knee OA prevalence) | India (one of the fastest-growing regions driven by rising ambulatory surgeries and aging demographics) |
Major Market Players & Market Structure
Market Structure: Highly competitive regional landscape featuring leading global biopharmaceutical and medical device manufacturers competing on advanced hyaluronic acid formulations, clinical trial pipelines, and localized distribution networks across Asia Pacific.
Key Companies: Sanofi S.A., Zimmer Biomet Holdings Inc., Bioventus LLC, Anika Therapeutics Inc., Fidia Farmaceutici S.p.A., Ferring B.V., Seikagaku Corporation, Chugai Pharmaceutical Co., Ltd., OrthogenRx Inc., and Mylan N.V.
Asia Pacific Viscosupplementation Market Size
The size of the Asia Pacific viscosupplementation market was worth USD 1.39 billion in 2025. The Asia Pacific market is anticipated to grow at a CAGR of 11.44% from 2026 to 2034 and be worth USD 3.68 billion by 2034 from USD 1.55 billion in 2026.
MARKET DRIVERS
Rising Osteoarthritis Cases Fuel Demand for Viscosupplementation in APAC
The rising population suffering from osteoarthritis is propelling the viscosupplementation market in APAC. In China, a significant portion of the aged people are suffering from knee OA and the prevalence is almost up to 22% in men and 43% in women. Most people feel continuous pain in their knees, leading to osteoarthritis. This condition is common in the joints of the knees, hands, feet, and hips and affects the spine and shoulder with growing age. It is a type of degenerative bone disease that is mainly seen in older populations over 65 years of age. According to the National Library of Medicine, 12.4% of the total population in the Asia-Pacific is of more than 60 years and nearly half of the older population suffers from osteoarthritis in this region. Viscosupplementation is one of the effective treatment procedures to reduce the pain in joints for patients by injecting a thick fluid named hyaluronate into the knee joints.
Furthermore, most people prefer non-surgical treatment for osteoarthritis. Many patients cannot opt for surgical procedures in the treatment of knee pains since the patient needs to meet certain health guidelines to be approved for surgery. As a result, the patients who do not match the criteria prefer injection-based treatment at regular intervals to reduce pain and increase the mobility of the body parts, which drives the APAC viscosupplementation market forward.
Technical Advancements in Hyaluronic Acid Therapies Drive APAC Viscosupplementation Market
Technical advancements in viscosupplementation treatment are another major factor accelerating the market growth. There are several treatments for knee pain in the region among which Hyaluronic acid, which is used in viscosupplementation treatment to reduce knee pain and swelling, is the most advanced treatment in this region. Several clinical trials are being conducted on the medicine injected into the knees to give more relief with fewer side effects. In addition, most researchers are working on developing an advanced treatment for this knee disorder so that older people can walk freely.
MARKET RESTRAINTS
High Costs, Side Effects, and Limited Expertise Hinder APAC Viscosupplementation Market
However, the high costs associated with the viscosupplementation treatment procedures and the side effects linked are a few of the factors hampering the market growth in the Asia-Pacific region. Strict government policies for using viscosupplementation treatment in some areas also hamper the market growth. The need for more skilled professionals in giving the treatment also impedes market growth. The dearth of researchers is a major problem faced when increasing the production of this drug as a smaller number of people for the research results in slower drug development and product launch which could in turn hamper the development of treatments.
GEOGRAPHICAL ANALYSIS

Geographically, Asia Pacific is the fastest-growing region in the global market and is expected to register a substantial share of the market during the forecast period owing to the increasing population preferring viscosupplementation treatment in this region. The prevalence of osteoarthritis is growing consistently in the Asia-Pacific region. The changing lifestyles of the people, including food habits, are causing the persistence of pain in the knee and joints in a large population from this region. Unhealthy food habits are another major cause that can lead to joint pains. Increasing obesity also results in osteoarthritis disease in many people. Depending upon the person's fluid levels in the joints, the dosage at intervals of 1 week, three weeks, or six months will be decided.
The Chinese viscosupplementation market is forecasted to account major chunk of the APAC regional market share during the forecast period. The growing number of people suffering from rheumatoid arthritis and the rising demand for non-surgical treatments for osteoarthritis are propelling the viscosupplementation market in China.
The Indian viscosupplementation market is one of the fastest-growing regions in the APAC regional market. Growing demand for ambulatory surgeries, increasing awareness around viscosupplementation in India and rising aging population are boosting the market growth in India.
During the forecast period, the viscosupplementation market in Japan is projected to grow at a healthy CAGR. In Japan, most of the younger patients are choosing this treatment. Due to the acceptance of intra-articular hyaluronic acid in the treatment of joint problems in this region, the market has a significant share. The availability of this medicine in online stores and near medical stores also drives the market forward. Launching of new products by many key players and the approvals of medicine for pain relief, joint problems, and knee problems also help market growth.
KEY MARKET PARTICIPANTS
A few of the noteworthy companies dominating the APAC viscosupplementation market analyzed in this report are Sanofi S.A., Zimmer Biomet Holdings Inc., Bioventus LLC, Anika Therapeutics Inc., Fidia Farmaceutici S.p.A., Ferring B.V., Seikagaku Corporation, Chungai Pharmaceutical Co., Ltd., OrthogenRx Inc., and Mylan N.V.
MARKET SEGMENTATION
This Asia Pacific viscosupplementation market research report is segmented and sub-segmented into the following categories.
By Product
- Single Injection
- Three Injection
- Five Injection
By End-Use
- Hospitals
- Orthopedic Clinic/ Ambulatory Surgical Centers (ASCs)
By Country
- India
- China
- Japan
- South Korea
- Australia
- New Zealand
- Thailand
- Malaysia
- Vietnam
- Philippines
- Indonesia
- Singapore
- Rest Of APAC
